Tipifarnib in Treating Patients With Advanced Hematologic Cancer

Phase 1 Completed 36 enrolled National Cancer Institute (NCI)

RandomizedSingle-groupOpen-labelTreatment

Summary

Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.

Timeline

Start: 2000-08
Primary completion: 2004-04
Completion: —

Publications

Results Zimmerman TM, Harlin H, Odenike OM, Berk S, Sprague E, Karrison T, Stock W, Larson RA, Ratain MJ, Gajewski TF. Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies. J Clin Oncol. 2004 Dec 1;22(23):4816-22. doi: 10.1200/JCO.2004.03.200.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	tipifarnib	Small molecule	100 mg	Oral
Subject	tipifarnib	Small molecule	200 mg	Oral
Subject	tipifarnib	Small molecule	300 mg	Oral
Subject	tipifarnib	Small molecule	600 mg	Oral

Tipifarnib in Treating Patients With Advanced Hematologic Cancer

Summary

Timeline

Publications

Drugs

Indications